NeuroMetrix Net Worth
NeuroMetrix Net Worth Breakdown | NURO |
NeuroMetrix Net Worth Analysis
NeuroMetrix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including NeuroMetrix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of NeuroMetrix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform NeuroMetrix's net worth analysis. One common approach is to calculate NeuroMetrix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares NeuroMetrix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing NeuroMetrix's net worth. This approach calculates the present value of NeuroMetrix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of NeuroMetrix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate NeuroMetrix's net worth. This involves comparing NeuroMetrix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into NeuroMetrix's net worth relative to its peers.
Enterprise Value |
|
To determine if NeuroMetrix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeuroMetrix's net worth research are outlined below:
| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (6.53 M) with profit before overhead, payroll, taxes, and interest of 2.2 M. | |
| NeuroMetrix currently holds about 20.83 M in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68. | |
| NeuroMetrix has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Comparing Adagio Medical NeuroMetrix |
NeuroMetrix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NeuroMetrix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NeuroMetrix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know NeuroMetrix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NeuroMetrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeuroMetrix backward and forwards among themselves. NeuroMetrix's institutional investor refers to the entity that pools money to purchase NeuroMetrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Fmr Inc | 2024-12-31 | 89.0 | |
| Bank Of America Corp | 2024-12-31 | 18.0 | |
| Harbour Investments, Inc. | 2024-12-31 | 11.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | |
| Stephens Consulting Llc | 2024-12-31 | 0.0 | |
| Vanguard Group Inc | 2024-12-31 | 15.1 K | |
| Mariner Wealth Advisors Llc | 2024-12-31 | 15.1 K | |
| Geode Capital Management, Llc | 2024-12-31 | 13.2 K | |
| Renaissance Technologies Corp | 2024-12-31 | 11.6 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 8.6 K |
Follow NeuroMetrix's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.09 M.Market Cap |
|
Project NeuroMetrix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.37) | (0.39) |
When accessing NeuroMetrix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures NeuroMetrix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeuroMetrix's profitability and make more informed investment decisions.
Evaluate NeuroMetrix's management efficiency
NeuroMetrix has return on total asset (ROA) of (0.2632) % which means that it has lost $0.2632 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4278) %, meaning that it created substantial loss on money invested by shareholders. NeuroMetrix's management efficiency ratios could be used to measure how well NeuroMetrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of March 2025, Return On Tangible Assets is likely to drop to -0.37. In addition to that, Return On Capital Employed is likely to drop to -0.43. At this time, NeuroMetrix's Non Currrent Assets Other are very stable compared to the past year. As of the 31st of March 2025, Other Current Assets is likely to grow to about 1.5 M, while Total Assets are likely to drop about 17.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 22.19 | 21.08 | |
| Tangible Book Value Per Share | 22.19 | 21.08 | |
| Enterprise Value Over EBITDA | (0.37) | (0.35) | |
| Price Book Value Ratio | 0.21 | 0.20 | |
| Enterprise Value Multiple | (0.37) | (0.35) | |
| Price Fair Value | 0.21 | 0.20 | |
| Enterprise Value | 7.7 M | 7.3 M |
The strategic initiatives led by NeuroMetrix's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.245 | Revenue | Quarterly Revenue Growth (0.51) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeuroMetrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeuroMetrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeuroMetrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeuroMetrix Corporate Filings
8K | 25th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 13th of February 2025 Other Reports | ViewVerify | |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
NeuroMetrix Earnings per Share Projection vs Actual
NeuroMetrix Corporate Executives
Elected by the shareholders, the NeuroMetrix's board of directors comprises two types of representatives: NeuroMetrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuroMetrix. The board's role is to monitor NeuroMetrix's management team and ensure that shareholders' interests are well served. NeuroMetrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuroMetrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Higgins | CFO, Principal Accounting Officer, Sr. VP and Treasurer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share | Quarterly Revenue Growth (0.51) | Return On Assets | Return On Equity |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.